Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

Blood (2017) 130 (20): 2196–2203.

https://doi.org/10.1182/blood-2017-06-788877

Published: 2017

Journal Articles

TARC Predicts PET-Normalization and Event Free Surival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated with Brentuximab Vedotin

Alison J Moskowitz, MD, Sun Cho, Martin Fleisher, PhD, Kaitlin M Woo, MS, Zhigang Zhang, PhD, Stephanie Fox, Susan J McCall, MSN ANP-BC, Heiko Schoder, MD, Joachim Yahalom, MD, Craig H Moskowitz, MD

Blood (2015) 126 (23): 180.

https://doi.org/10.1182/blood.V126.23.180.180

Published: 2015

Journal Articles

Generation of a Novel, Multi-Stage, Progressive, and Transplantable Model of Multiple Myeloma

Takashi Asai, MD, PhD, Silvia Menendez, Delphine Ndiaye-Lobry, Anthony R Deblasio, Kazunori Murata, PhD, Martin Fleisher, PhD, John Petrini, PhD, Stephen D Nimer, MD

Blood (2012) 120 (21): 327.

https://doi.org/10.1182/blood.V120.21.327.327

Published: 2012

Journal Articles

Effects of Long Term Imatinib on Bone Mineral Density In Patients with Chronic Myelogenous Leukemia (CML) or Gastrointestinal Stromal Tumor (GIST)

Ellin Berman, MD, Robert Maki, MD, PhD, Azeez Farooki, MD, Monica Girotra, MD, Suzanne Chanel, RN, Catherine Cheng, BA, H. William Strauss, MD, Martin Fleisher, PhD

Blood (2010) 116 (21): 2276.

https://doi.org/10.1182/blood.V116.21.2276.2276

Published: 2010

Journal Articles

CD32B Expression Reflects Phenotypic and Functional Heterogeneity in Multiple Myeloma (MM)

Ping Zhou, MD, PhD, Adam M Boruchov, MD, James E. Hoffman, MD, Qianxing Mo, Adam Olshen, Evan Glasner, Ezio Bonvini, Scott Koenig, Ellen Drieghe, Martin Fleisher, PhD, Peter Maslak, MD, Hani Hassoun, MD, Adam D Cohen, MD, Heather Landau, MD, James W. Young, MD, Suresh C Jhanwar, PhD, Stephen D Nimer, MD, Raymond L Comenzo

Blood (2008) 112 (11): 842.

https://doi.org/10.1182/blood.V112.11.842.842

Published: 2008

Journal Articles

CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody–based therapy

Ping Zhou, Raymond L. Comenzo, Adam B. Olshen, Ezio Bonvini, Scott Koenig, Peter G. Maslak, Martin Fleisher, James Hoffman, Suresh Jhanwar, James W. Young, Stephen D. Nimer, Adam M. Boruchov

Blood (2008) 111 (7): 3403–3406.

https://doi.org/10.1182/blood-2007-11-125526

Published: 2008

Journal Articles

Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan

Ping Zhou, Julie Teruya-Feldstein, Ping Lu, Martin Fleisher, Adam Olshen, Raymond L Comenzo

Blood (2008) 111 (2): 549–557.

https://doi.org/10.1182/blood-2007-05-090852

Published: 2008

Journal Articles

Predictors of Survival in De Novo Cardiac Amyloidosis.

Raymond L. Comenzo, MD, Mathew Maurer, MD, Adam Cohen, MD, Hani Hassoun, MD, Ping Zhou, PhD, Ping Lu, PhD, Martin Fleisher, PhD, Daniel Lebovic, MD, Julie Feldstein, MD, Richard Steingart, MD, Stephen D. Nimer, MD

Blood (2007) 110 (11): 2870.

https://doi.org/10.1182/blood.V110.11.2870.2870

Published: 2007

Journal Articles

Mobilization of Blood Stem Cells with G-CSF in Systemic Light-Chain Amyloidosis: Dominant Organ Involvement Significantly Affects Stem Cell Collection.

Raymond Comenzo, MD, Hani Hassoun, MD, Lilian Reich, MD, Nancy Collins, PhD, Andre Nuta, Xiaoshe Chen, PhD, Ping Zhou, MD. PhD, Bradly Clark, MD, Julie Teruya-Feldstein, MD, Martin Fleisher, PhD, David Wuest, MD, Stephen D. Nimer, MD

Blood (2006) 108 (11): 3087.

https://doi.org/10.1182/blood.V108.11.3087.3087

Published: 2006

Journal Articles

Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins

Raymond L. Comenzo, Ping Zhou, Martin Fleisher, Bradly Clark, Julie Teruya-Feldstein

Blood (2006) 107 (9): 3489–3491.

https://doi.org/10.1182/blood-2005-10-4148

Published: 2006

Journal Articles

Adjuvant Dexamethasone (D) ± Thalidomide (T) Improves Hematologic and Organ Responses after Risk-Adapted High-Dose Melphalan with Autologous Stem Cell Transplant (SCT) for Patients with Systemic AL Amyloidosis (AL).

Adam D. Cohen, MD, Ping Zhou, MD, PhD, Lillian Reich, MD, Hani Hassoun, MD, Julie Teruya-Feldstein, MD, Daniel A. Filippa, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2005) 106 (11): 1163.

https://doi.org/10.1182/blood.V106.11.1163.1163

Published: 2005

Journal Articles

Risk-Adapted Dosing of Melphalan for Systemic AL Amyloidosis (AL) Lowers Treatment-Related Mortality: Early Death but Not Post-3 Month Survival Is Linked to Cardiac Involvement.

Raymond L. Comenzo, MD, Ping Zhou, MD, PhD, Hani Hassoun, MD, Tarun Kewalramani, MD, Virginia Klimek, MD, Adam D. Cohen, MD, Susane K. Ferrand, MD, Madhav Dhodapkar, MD, Julie Teruya-Feldstein, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD

Blood (2005) 106 (11): 1156.

https://doi.org/10.1182/blood.V106.11.1156.1156

Published: 2005

Journal Articles

The Abdominal Fat Pad Aspirate for Diagnosing Amyloidosis Is a Useful Tool.

Bradly D. Clark, MD, Oscar Lin, MD, PhD, Andre Moreira, MD, Julie Teruya-Feldstein, MD, Cristina R. Antonescu, MD, Hani Hassoun, MD, Ping Zhou, MD, PhD, Martin Fleisher, PhD, Raymond L. Comenzo, MD

Blood (2005) 106 (11): 5107.

https://doi.org/10.1182/blood.V106.11.5107.5107

Published: 2005

Journal Articles

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Hani Hassoun, MD, Lilian Reich, MD, Virginia M. Klimek, MD, Madhav Dhodapkar, MD, Adam Cohen, MD, Tarun Kewalramani, MD, Elyn R. Riedel, MA, Cyrus V. Hedvat, MD, Julie Teruya-Feldstein, MD, Daniel A. Filippa, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2005) 106 (11): 3481.

https://doi.org/10.1182/blood.V106.11.3481.3481

Published: 2005

Journal Articles

Seeking Diagnostic Confidence in Typing Amyloidosis: Prospective Results with an Algorithm To Minimize Misdiagnosis of Immunoglobulin Light-Chain (AL) Amyloidosis.

Raymond L. Comenzo, MD, Ping Zhou, MD, PhD, Limin Wang, PhD, Bradly D. Clark, MD, Martin Fleisher, PhD, Julie Teruya-Feldstein, MD

Blood (2005) 106 (11): 5099.

https://doi.org/10.1182/blood.V106.11.5099.5099

Published: 2005

Journal Articles

Altered Bone and Mineral Metabolism in Patients Treated with Imatinb.

Ellin Berman, MD, Maria Nicolaides, MD, Nicolas Sauter, MD, Suzanne Chanel, RN, Brianne Wilson, Martin Fleisher, PhD

Blood (2004) 104 (11): 4668.

https://doi.org/10.1182/blood.V104.11.4668.4668

Published: 2004

Journal Articles

Frequency of Molecular and PET/CT Complete Remissions in Patients with Multiple Myeloma after Autologous Followed by Reduced-Intensity Allogeneic Stem Cell Transplants.

Ping Zhou, MD, PhD, Hugo Castro-Malaspina, MD, Esperanza B. Papadopoulos, MD, James W. Young, MD, Kenneth Miller, MD, Neeta Pandit-Taskar, MD, Daniel A. Filippa, MD, Martin Fleisher, PhD, Raymond L. Comenzo, MD

Blood (2004) 104 (11): 5113.

https://doi.org/10.1182/blood.V104.11.5113.5113

Published: 2004

Journal Articles

Risk-Adapted Intravenous Melphalan Followed by Adjuvant Dexamethasone (D) and Thalidomide (T) for Newly Diagnosed Patients with Systemic AL Amyloidosis (AL): Interim Results of a Phase II Study.

Adam D. Cohen, Ping Zhou, Lillian Reich, Alice Quinn, Sophia Fircanis, Lisa Drake, Cyrus Hedvat, Julie Teruya-Feldstein, Daniel A. Filippa, Martin Fleisher, Raymond L. Comenzo

Blood (2004) 104 (11): 542.

https://doi.org/10.1182/blood.V104.11.542.542

Published: 2004

Journal Articles

Low Bone Mass in Thalassemia: The Thalassemia Clinical Research Network (TCRN) Experience.

Maria G. Vogiatzi, MD, Joseph Lane, MD, Martin Fleisher, MD, Eric A. Macklin, PhD, Ellen B. Fung, PhD, Melanie Kirby, MD, Janet Kwiatkowski, MD, Ingrid Holm, MD, Nancy Olivieri, MD, Elliott Vichinsky, MD, Patricia J. Giardina, MD

Blood (2004) 104 (11): 3613.

https://doi.org/10.1182/blood.V104.11.3613.3613

Published: 2004

NARROW

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

TARC Predicts PET-Normalization and Event Free Surival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated with Brentuximab Vedotin

Generation of a Novel, Multi-Stage, Progressive, and Transplantable Model of Multiple Myeloma

Effects of Long Term Imatinib on Bone Mineral Density In Patients with Chronic Myelogenous Leukemia (CML) or Gastrointestinal Stromal Tumor (GIST)

CD32B Expression Reflects Phenotypic and Functional Heterogeneity in Multiple Myeloma (MM)

CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody–based therapy

Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan

Predictors of Survival in De Novo Cardiac Amyloidosis.

Mobilization of Blood Stem Cells with G-CSF in Systemic Light-Chain Amyloidosis: Dominant Organ Involvement Significantly Affects Stem Cell Collection.

Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins

Adjuvant Dexamethasone (D) ± Thalidomide (T) Improves Hematologic and Organ Responses after Risk-Adapted High-Dose Melphalan with Autologous Stem Cell Transplant (SCT) for Patients with Systemic AL Amyloidosis (AL).

Risk-Adapted Dosing of Melphalan for Systemic AL Amyloidosis (AL) Lowers Treatment-Related Mortality: Early Death but Not Post-3 Month Survival Is Linked to Cardiac Involvement.

The Abdominal Fat Pad Aspirate for Diagnosing Amyloidosis Is a Useful Tool.

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Seeking Diagnostic Confidence in Typing Amyloidosis: Prospective Results with an Algorithm To Minimize Misdiagnosis of Immunoglobulin Light-Chain (AL) Amyloidosis.

Altered Bone and Mineral Metabolism in Patients Treated with Imatinb.

Frequency of Molecular and PET/CT Complete Remissions in Patients with Multiple Myeloma after Autologous Followed by Reduced-Intensity Allogeneic Stem Cell Transplants.

Risk-Adapted Intravenous Melphalan Followed by Adjuvant Dexamethasone (D) and Thalidomide (T) for Newly Diagnosed Patients with Systemic AL Amyloidosis (AL): Interim Results of a Phase II Study.

Low Bone Mass in Thalassemia: The Thalassemia Clinical Research Network (TCRN) Experience.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only